Table 3.
The distribution of pathological findings based on gender and different age groups.
| Histologic diagnosis | Age (years old) | |||||
|---|---|---|---|---|---|---|
| ≤ 14, N (%) | 15–19, N (%) | 20–39, N (%) | 40–59, N (%) | ≥ 60, N (%) | Total, N (%) | |
| PGN (22,529, 65.06%) | ||||||
| MN | 72 (2.13) | 240 (11.07) | 2,149 (17.41) | 4,235 (34.67) | 1,948 (43.03) | 8,644 (24.96) |
| IgAN | 735 (21.78) | 447 (20.61) | 4,064 (32.92) | 2,647 (21.67) | 450 (9.94) | 8,343 (24.09) |
| MCD | 633 (18.76) | 551 (25.40) | 1,383 (11.20) | 813 (6.66) | 330 (7.29) | 3,710 (10.71) |
| FSGS | 112 (3.32) | 72 (3.32) | 324 (2.62) | 210 (1.72) | 132 (2.92) | 850 (2.45) |
| MPGN | 10 (0.30) | 2 (0.09) | 70 (0.57) | 98 (0.80) | 30 (0.66) | 210 (0.61) |
| C3 glomerulopathy | 10 (0.30) | 2 (0.09) | 16 (0.13) | 12 (0.10) | 8 (0.18) | 48 (0.14) |
| Postinfectious GN | 84 (2.49) | 16 (0.74) | 34 (0.28) | 23 (0.19) | 19 (0.42) | 176 (0.51) |
| MN + IgAN | 1 (0.03) | 11 (0.51) | 144 (1.17) | 243 (1.99) | 52 (1.15) | 451 (1.30) |
| MCD + IgAN | 7 (0.21) | 17 (0.78) | 49 (0.40) | 17 (0.14) | 7 (0.15) | 97 (0.28) |
| SGN (7,622, 22.01%) | ||||||
| LN | 233 (6.91) | 245 (11.30) | 1,433 (11.61) | 663 (5.43) | 42 (0.93) | 2,616 (7.55) |
| HSPN | 1,078 (31.95) | 216 (9.96) | 318 (2.58) | 213 (1.74) | 87 (1.92) | 1,912 (5.52) |
| HBV-GN | 86 (2.55) | 116 (5.35) | 424 (3.43) | 228 (1.87) | 96 (2.12) | 950 (2.74) |
| DN | 0 (0) | 1 (0.05) | 113 (0.92) | 591 (4.84) | 234 (5.17) | 939 (2.71) |
| ORG | 1 (0.03) | 7 (0.32) | 220 (1.78) | 214 (1.75) | 21 (0.46) | 463 (1.34) |
| paraprotein-GN | 0 (0) | 0 (0) | 10 (0.08) | 172 (1.41) | 206 (4.55) | 388 (1.12) |
| pauci-immune GN | 3 (0.09) | 3 (0.14) | 21 (0.17) | 115 (0.94) | 187 (4.13) | 329 (0.95) |
| Anti-GBM | 0 (0) | 1 (0.05) | 9 (0.07) | 11 (0.09) | 4 (0.09) | 25 (0.07) |
| TID (884, 2.55%) | ||||||
| AIN | 9 (0.27) | 13 (0.60) | 80 (0.65) | 184 (1.51) | 109 (2.41) | 395 (1.14) |
| ATN | 12 (0.36) | 14 (0.65) | 103 (0.83) | 150 (1.23) | 64 (1.41) | 343 (0.99) |
| CTIN | 2 (0.06) | 3 (0.14) | 16 (0.13) | 35 (0.29) | 16 (0.35) | 72 (0.21) |
| Cast nephropathy | 0 (0) | 0 (0) | 0 (0) | 33 (0.27) | 41 (0.91) | 74 (0.21) |
| Vascular diseases (594, 1.72%) | ||||||
| Hypertensive nephrosclerosis | 0 (0) | 3 (0.14) | 227 (1.84) | 190 (1.56) | 37 (0.82) | 457 (1.32) |
| TMA | 24 (0.71) | 4 (0.18) | 45 (0.36) | 38 (0.31) | 26 (0.57) | 137 (0.40) |
| HCRD | 55 (1.63) | 10 (0.46) | 42 (0.34) | 27 (0.22) | 3 (0.07) | 137 (0.40) |
| Miscellaneous | 207 (6.14) | 175 (8.07) | 1,051 (8.51) | 1,053 (8.62) | 378 (8.35) | 2,864 (8.27) |
| Total | 3,374 (100) | 2,169 (100) | 12,345 (100) | 12,215 (100) | 4,527 (100) | 34,630 (100) |
PGN primary glomerulonephritis, SGN secondary glomerulonephritis, TID tubulointerstitial diseases, HCRD hereditary and congenital renal disease, MN membranous nephropathy, IgAN IgA nephropathy, MCD minimal change disease, FSGS focal segmental glomerulosclerosis, MPGN membranoproliferative glomerulonephritis, MN + IgAN MN combined with IgAN, MCD + IgAN MCD combined with IgAN, LN lupus nephritis, HSPN Henöch–Schönlein purpura nephritis, HBV-GN hepatitis B virus associated glomerulonephritis, DN diabetic nephropathy, ORG obesity-related glomerulopathy, paraprotein-GN paraprotein-associated glomerulopathy, pauci-immune GN pauci-immune/ANCA-associated glomerulonephritis, Anti-GBM anti-GBM nephritis, AIN acute interstitial nephritis, ATN acute tubular necrosis, CTIN chronic tubulointerstitial nephritis. Cast nephropathy, light chain cast nephropathy, TMA thrombotic microangiopathy.